News
Media
Around the PracticeBetween The LinesCase-Based Peer PerspectiveClinical Case CollectiveDermViewExpert PerspectivesFellows Face OffFrontline ForumMedical World NewsPatient PerspectivesPodcastsReadout360Recognize and Refer
Conferences
Conference CoverageConference Listing
Events
Case-Based Roundtable
Publication
Dermatology Times
More
CME/CE
Resources
DermIQInteractive ToolsJob BoardPartner PerspectivesPerspectives in DermatologyPollsSponsored ContentSponsored ResourcesSpot Test
Editorial Advisory Board
Partners

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publication
  • CME/CE
  • Resources
  • Editorial Advisory Board
  • Partners
  • Subscribe
  • Acne
  • Actinic Keratosis
  • Aesthetics
  • Alopecia
  • Atopic Dermatitis
    • Biologic Treatments for Moderate to Severe Atopic Dermatitis
  • Buy-and-Bill
  • COVID-19
  • Case-Based Roundtable
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Drug Watch
  • Eczema
  • General Dermatology
  • Hidradenitis Suppurativa
  • Melasma
  • Pediatric Dermatology
  • Pigmentary Disorders
  • Practice Management
  • Precision Medicine and Biologics
  • Prurigo Nodularis
  • Psoriasis
    • Emerging Therapies Plaque Psoriasis
    • Treatments for Plaque Psoriasis
  • Psoriatic Arthritis
  • Rare Disease
  • Rosacea
  • Skin Cancer
    • Skin Cancer (Nonmelanoma)
  • Vitiligo
  • Wound Care
Spotlight -
Derm NP/PA Connect
Advertisement

Jordan Miller, MD

Advertisement

Articles by Jordan Miller, MD

Jordan Miller, MD: 2024 Dermatology Predictions

ByKaitlyn Bader, Senior Editor ,Jordan Miller, MD
January 23rd 2024

Advancements in assistance from artificial intelligence include ambient listening to take notes during physician and patient conversations.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Dermatology Times

    1

    Phase 3 Data Position Zasocitinib as a Potential New Oral Option for Psoriasis

    2

    Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025

    3

    First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA

    4

    Topicals Demonstrate Targeted Control Across 3 Distinct Atopic Dermatitis Cases

    5

    Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 2

    • About
    • Advertise
    • Contact Us
    • Job Board
    • Do Not Sell My Information
    • Terms and Conditions
    • Privacy Policy
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us